Aclarion Names Daniel Keefe Western U.S. Director After Triple-Digit Nociscan Growth
Aclarion has appointed Daniel Keefe as Commercial Director for the Western U.S., aiming to drive adoption of its Nociscan low back pain diagnostic. His appointment follows triple-digit growth in Nociscan utilization across academic institutions and high-volume private spine centers.
1. Leadership Appointment
Aclarion has named Daniel Keefe as Commercial Director for the Western U.S., charging him with building on existing relationships at academic institutions and high-volume private spine centers. Keefe brings over 20 years of medical device and healthcare technology sales experience from roles at Centinel Spine, Brainlab, Zimmer Biomet and Intuitive Surgical.
2. Commercial Expansion and Growth
The expansion of Aclarion’s commercial team reflects sustained demand for Nociscan, driven by triple-digit growth in utilization across key Western U.S. markets. Keefe will oversee territory development, surgeon engagement and market penetration to support continued volume gains.
3. Nociscan Technology and Impact
Nociscan is a cloud-based platform that noninvasively quantifies chemical biomarkers via magnetic resonance spectroscopy to pinpoint painful lumbar discs. When integrated with other diagnostic tools, the solution has demonstrated a 97% surgical success rate for treated Nociscan-positive discs, underscoring its clinical value.